3 Blockbuster Drugs That Still Cost More Than They Should

3 Blockbuster Drugs That Still Cost More Than They Should

Asking, "Is there a generic for that?" usually saves a bundle when your doctor prescribes an expensive brand-name drug. If you're one of the thousands of Americans who rely on Humira, Enbrel, or Remicade, though, odds are you'll still be paying through the nose for branded versions of these drugs, sold by AbbVie (NYSE: ABBV), Amgen (NASDAQ: AMGN), and Johnson & Johnson (NYSE: JNJ), respectively. 

Even though the Food and Drug Administration has already approved copycat versions to be sold at a discount, U.S. sales of these three blockbuster drugs keep rising and are on pace to reach a combined $21 billion this year. So you might be surprised to learn that countries other than the U.S. are spending less on all of these drugs than they did a few years ago.

Images source: Getty Images

Continue reading

Source: Fool.com